Lotte Bio Signs MOU with Exelixis and Cana Therapeutics for ADC Development

Lotte Biologics has signed an MOU with Exelixis and Cana Therapeutics to jointly develop next-generation ADC cancer therapies, focusing on linker and payload technologies to enhance global competitiveness.